Diabetes screening · before surgery

Preoperative Diabetes Screening Before Pain Procedures and Surgery

Preoperative diabetes screening means drawing an HbA1c before a pain procedure or surgery, and it belongs on every patient: universal screening in one arthroplasty program found diabetes or prediabetes in more than half, with 40.9% of the diabetic patients undiagnosed. An HbA1c above 8% before lumbar surgery was tied to more complications and readmissions.

Pain care escalates from pills to needles to the operating room, usually without one metabolic number drawn. Screening everyone shows what that omission hides.

Preoperative diabetes screening is standard in some arthroplasty programs and missing from most pain pathways, even though the unmeasured glycemia that complicates a fusion also shapes what an epidural, a drug trial or a lifestyle program delivers. The escalation ladder in pain care usually climbs from medication to injection to surgery without a single metabolic measurement on the way up.

Pain Is Not a Diagnosis, the Chapter 2 video of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, frames pain as a signal that raises three questions before anyone treats it: which structure, which mechanism, which terrain. For a referring or treating physician, the third question is a measurement problem, and part of the second is one too.

How the label replaced the workup

ICD-11 codes chronic primary pain when pain has lasted beyond three months with distress or disability and is not better accounted for by another condition. It works as a coding instrument, yet no biological criterion separates primary from secondary pain; the category is defined by what was not found. A label built from exclusion gives a clinician nowhere to go next.

For about two decades the field, Dr. Padda’s own specialty among them, treated the pain score as the endpoint. The numeric rating became a vital sign, and a review of 600 VA visits found no quality indicator improved afterward. The incentives reinforced it: 83% of academic pain-center leaders reported administrative pressure tied to satisfaction scores, while in 51,946 nationally representative adults the most-satisfied quartile carried an adjusted mortality hazard of 1.26. A metric that rewards a quiet patient does not reward a measured one.

How often does preoperative screening find undiagnosed diabetes?

Screen every patient and the prevalence stops being theoretical. In a Philadelphia arthroplasty population of 1,461, diabetes was present in 20.6% and prediabetes in 38.3%, and 40.9% of the diabetic patients carried no prior diagnosis. Universal HbA1c testing before knee replacement in Hong Kong added undiagnosed prediabetes in 36.4% and undiagnosed diabetes in 1.6%. Most of those patients had been through primary care and a surgical referral without the number being drawn.

The value predicts the result. In 4,778 elective lumbar operations, preoperative HbA1c above 8% was associated with an odds ratio of 1.81 for any complication, 1.66 for 90-day readmission and 0.64 for reaching a meaningful functional gain. In a matched analysis of 7,336 arthrodesis patients with diabetes, 30-day readmission ran 6.5% against 4.4% and 90-day reoperation 4.3% against 3.2%, with no difference after decompression alone. Across more than 3 million spine operations, metabolic syndrome carried relative risks of 1.5 for readmission and 1.6 for wound complications.

The evidence is observational, diabetes is often a registry checkbox rather than a measured value, and one cohort of 587 hip and knee replacements found similar 12-month pain and function once BMI and comorbidity were adjusted. That study supports obesity plus multimorbidity as the operative terrain rather than HbA1c alone, which is still an argument for measuring the terrain.

Do steroid injections raise blood sugar?

The same body receives the injections. In a multicenter cervical epidural cohort, 92% of diabetic patients developed transient hyperglycemia, and in 18 patients measured serially, fasting glucose was elevated on day 1 and back to baseline by day 7. Bone density reductions appeared at a cumulative methylprednisolone-equivalent dose of 200 mg in a year, against real-world exposure averaging 14.7 injections per patient. An epidural used as a bridge on a patient with known metabolic status is a defensible plan. The same injection repeated on an unmeasured body is exposure without a denominator.

Practically, a known HbA1c before a steroid procedure lets the team set a glucose-monitoring plan for the following week and track cumulative steroid dose against a bone-health baseline, instead of discovering the diabetes after the second or third injection.

Mechanism is also unmeasured

Physical examination alone is Level IV evidence for identifying a spinal pain generator and MRI or CT Level V, so a structural answer needs a controlled block. Mechanism is skipped even more often. Of 27 trials of neuropathic-pain drugs for back and spine-related leg pain, 59% excluded neuropathic pain or never assessed it, and only 22% enrolled patients at the probable-or-definite level. Where neuropathic pain was probable, pain fell 10.45 points on a 100-point scale; where merely possible, 5.50, though subgroup differences were not significant. In one clinic sample of 1,957 patients, 13.0% screened positive for a neuropathic component, with no correlation to pain duration.

A validated screening questionnaire belongs in the intake. Where small-fiber involvement is suspected, sudomotor testing adds an objective read on the sweat response driven by small distal nerve fibers, which helps separate a neuropathic contribution from a purely structural one before drug selection.

Why measure a metabolic baseline before treating pain?

The terrain trials show pain responding in proportion to metabolic change. In 407 adults with obesity and knee osteoarthritis, semaglutide reduced knee pain by 41.7 points against 27.5 for placebo over 68 weeks with weight loss of 13.7% against 3.2%. Metformin in 107 adults with knee osteoarthritis and overweight reduced pain by 11.4 mm more than placebo. Intensive diet and exercise produced 10.6 kg of weight loss with a fall in IL-6, while the community version of the same program moved pain by only 0.6 points, and a telephone referral that changed weight by 0.4 kg changed pain not at all.

The less obvious consequence is diagnostic. Without a baseline body composition and metabolic panel, a patient who fails a lifestyle or pharmacologic plan cannot be classified: the terrain may not have changed, or it changed and the pain generator lies elsewhere. Repeat measurement is what distinguishes a failed intervention from a failed dose. Serial values also support between-visit monitoring in chronic care.

What should a preoperative diabetes screening order set include?

Guidelines will not supply it. The 2022 CDC opioid-prescribing guideline runs 95 pages without mentioning HbA1c, insulin or an inflammatory marker, and the NICE chronic pain assessment section sets out 23 recommendations naming no blood test. Neither prohibits testing; both leave a vacancy that a practice has to fill with its own protocol.

A workable protocol attaches a standing order to any referral for fusion, arthroplasty or repeated steroid injection: HbA1c and fasting glucose against the published thresholds of 6.5% and 126 mg/dL for diabetes and 5.7-6.4% and 100-125 mg/dL for prediabetes, fasting insulin and lipids through laboratory panels, bioimpedance body composition, a mood screen and a neuropathic screen. Measura [Cardiometabolic and Autonomic Health Analysis] performs and reports those measurements under physician medical direction; interpretation and management remain with the ordering and treating physicians, and results should travel to the surgeon through structured record integration. The study-level evidence is in the Chapter 2 supplement, and the mortality case for screening pain patients at all is in the physician article on metabolic screening in chronic pain. Excess weight can hide depleted muscle and micronutrients before an operation, the focus of malnutrition in obesity.

Frequently asked questions

References

• Shohat, N., Goswami, K., Tarabichi, M., Sterbis, E., Tan, T. L., & Parvizi, J. (2018). All Patients Should Be Screened for Diabetes Before Total Joint Arthroplasty. The Journal of Arthroplasty, 33(7), 2057–2061. https://doi.org/10.1016/j.arth.2018.02.047
• Lim, S., Yeh, H. H., Macki, M., Mansour, T., Schultz, L., Telemi, E., Haider, S., Nerenz, D. R., Schwalb, J. M., Abdulhak, M., Park, P., Aleem, I., Easton, R., Khalil, J., Perez-Cruet, M., & Chang, V. (2021). Preoperative HbA1c > 8% Is Associated With Poor Outcomes in Lumbar Spine Surgery: A Michigan Spine Surgery Improvement Collaborative Study. Neurosurgery, 89(5), 819–826. https://doi.org/10.1093/neuros/nyab294
• Mooney, J., Nathani, K. R., Zeitouni, D., Michalopoulos, G. D., Wang, M. Y., Coric, D., Chan, A. K., Lu, D. C., Sherrod, B. A., Gottfried, O. N., Shaffrey, C. I., Than, K. D., Goldberg, J. L., Hussain, I., Virk, M. S., Agarwal, N., Glassman, S. D., Shaffrey, M. E., Park, P., … Bydon, M. (2023). Does diabetes affect outcome or reoperation rate after lumbar decompression or arthrodesis? A matched analysis of the Quality Outcomes Database data set. Journal of Neurosurgery: Spine, 40(3), 331-342. https://doi.org/10.3171/2023.9.SPINE23522
• Lenguerrand, E., Beswick, A. D., Whitehouse, M. R., Wylde, V., & Blom, A. W. (2018). Outcomes following hip and knee replacement in diabetic versus nondiabetic patients and well versus poorly controlled diabetic patients: a prospective cohort study. Acta Orthopaedica, 89(4), 399-405. https://doi.org/10.1080/17453674.2018.1473327
• Gogol, P., Pasztaleniec, R., Szczepaniak, R., Wiśniewski, R., Staszkiewicz, R., Sobstyl, M., Wąsik, P., & Grabarek, B. O. (2026). Clinical Outcomes of Two Institution-Specific Cervicothoracic Interlaminar Epidural Steroid Injection Protocols (C7/T1-6 mL vs. T1/T2-8 mL) in Cervical Radiculopathy: A Multicenter Retrospective Cohort Study. Journal of Clinical Medicine, 15(15), 5900. https://doi.org/10.3390/jcm15155900
• Ward, J., Grinstead, A., Kemp, A., Kersten, P., Schmid, A. B., & Ridehalgh, C. (2024). A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain? Drugs, 84(12), 1603–1636. https://doi.org/10.1007/s40265-024-02085-6
• Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine, 391(17), 1573–1583. https://doi.org/10.1056/NEJMoa2403664
• Messier, S. P., Beavers, D. P., Queen, K., Mihalko, S. L., Miller, G. D., Losina, E., Katz, J. N., Loeser, R. F., DeVita, P., Hunter, D. J., Newman, J. J., Quandt, S. A., Lyles, M. F., Jordan, J. M., & Callahan, L. F. (2022). Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial. JAMA, 328(22), 2242–2251. https://doi.org/10.1001/jama.2022.21893
• Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR. Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1

Related reading

• Metabolic Screening in Chronic Pain: Who to Test and What Changes
• Imaging for Low Back Pain and the Metabolic Workup the MRI Skips
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.